Vertex Inc. has promoted Peter Mueller, the company's EVP for drug innovation and realization and chief scientific officer, to an expanded role that covers all of Vertex's global research and development.
Mueller's new brief will include clinical and non-clinical development, clinical operations, medical and regulatory affairs for the company. Mueller will become Vertex's EVP for global research and development and chief scientific officer.
Prior to joining Vertex in 2003, Mueller held worldwide responsibility for development of all drug candidates as SVP of research and development for Boehringer Ingelheim Pharmaceuticals.
Freda Lewis-Hall, Vertex's current EVP and chief medical officer, will be departing Vertex on May 15.
Cambridge, Massachusetts-based Vertex Pharmaceuticals is a biotechnology company focused on the discovery and development of small molecule drugs for serious diseases.
The company's strategy is to commercialize its products both independently and in collaboration with major pharmaceutical companies. Vertex's product pipeline is focused on viral diseases, inflammation, autoimmune diseases, cancer, pain and cystic fibrosis. Vertex co-discovered the HIV protease inhibitor, Lexiva, with GlaxoSmithKline.
No comments:
Post a Comment